After decades of unprofitable operations, Antares Pharma (ATRS) achieved profitability in Q3 2019 with impressive revenue growth of 92.7% YOY. For Q3 ending September 30, the company reported revenue of $34.3 million and net income of $1.0 million. As noted in the table below, revenue has increased dramatically over the last six quarters, with a CAGR of 28.5% over the period.
(Source: Form 10K and Form 10Q for respective periods)
Particularly notable is the fact that, while revenue grew at a CAGR of 28.5%, operating expenses increased only 14.7%, pointing to a fact